MedTrace Logo

Adherence to Lenalidomide Treatment in Multiple Myeloma - Prevalence, Characteristics and Clinical Significance

NCT02733224 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2016-06-03

No results posted yet for this study

Summary

we intend to evaluate the association between non-adherence to Lenalidomide in Multiple Myeloma (MM) patients and overall response rates and time to progression (TTP).

Adherence will be measured in several ways, including by electronic monitoring, which is the gold standard method.

Conditions

  • Patient Non-adherence

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2017-03-31
Completion
2018-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02733224 on ClinicalTrials.gov